Serum procarboxypeptidase A and carboxypeptidase A levels in pancreatic disease

14Citations
Citations of this article
12Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

Background and objectives: To determine the serum levels of procarboxypeptidase A (pro-CPA) and carboxypeptidase A (CPA) in patients with acute and chronic pancreatitis and pancreatic cancer. Materials and methods: Serum samples obtained from 96 patients with acute pancreatitis, 101 patients with chronic pancreatitis, 98 patients with pancreatic cancer and 96 control groups were assayed for biochemical parameters and serum pro-CPA and CPA. Results: Serum pro-CPA and CPA levels were significantly higher in acute and in chronic pancreatic cancer patients compared to control group (p < 0.001). Pancreatic cancer patients had significantly higher serum pro-CPA and CPA levels when compared with acute and chronic pancreatitis cases (p < 0.001). Conclusion: These data prove for increased pro-CPA and CPA levels as a biomarker for the diagnosis of pancreatitis and pancreatic cancer. © 2012 The Author(s).

Cite

CITATION STYLE

APA

Kemik, O., Kemik, A. S., Sumer, A., Beǧenik, H., Dülger, A. C., Purisa, S., & Tuzun, S. (2012). Serum procarboxypeptidase A and carboxypeptidase A levels in pancreatic disease. Human and Experimental Toxicology, 31(5), 447–451. https://doi.org/10.1177/0960327111405864

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free